PAPER Tsivgoulis G, Bonakis A, Papathanasiou MA, Chondrogianni M, Papageorgiou SG, Voumvourakis K, Stefanis L
SEARCH RESULTS
329940 RESULTS
PAPER Mackin RS, Nelson JC, Delucchi KL, Raue PJ, Satre DD, Kiosses DN, Alexopoulos GS, Arean PA
Association of Age at Depression Onset with Cognitive Functioning in Individuals with Late-Life Depression and Executive Dysfunction.
Am J Geriatr Psychiatry. 2014 Feb 26; PubMed: 24680502PAPER González-Colaço Harmand M, Meillon C, Rullier L, Avila-Funes JA, Bergua V, Dartigues JF, Amieva H
Cognitive decline after entering a nursing home: a 22-year follow-up study of institutionalized and noninstitutionalized elderly people.
J Am Med Dir Assoc. 2014 Jul;15(7):504-8. Epub 2014 Mar 26 PubMed: 24679926PAPER Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson's Psychosis.
Neurochem Res. 2014 Mar 30; PubMed: 24682754PAPER Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.
Hum Mol Genet. 2014 Aug 15;23(16):4201-14. Epub 2014 Mar 27 PubMed: 24682598PAPER Bhidayasiri R, Mekawichai P, Jitkritsadakul O, Panyakaew P, Kaewwilai L, Boonrod N, Petchrutchatachart S, Jagota P, Boonpeng K, Singmaneesakulchai S, Setthawatcharawanich S
Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study.
J Neural Transm. 2014 Mar 31; PubMed: 24682359PAPER Campbell AW
Parkinson's Disease: A Brief Review.
Adv Mind Body Med. 2014 Spring;28(2):4-5. PubMed: 24681998PAPER Smith KM, Dahodwala N
Sex differences in Parkinson's disease and other movement disorders.
Exp Neurol. 2014 Mar 28; PubMed: 24681088PAPER Wu Y, Guo XY, Wei QQ, Song W, Chen K, Cao B, Ou RW, Zhao B, Shang HF
Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China.
J Neurol Sci. 2014 May 15;340(1-2):144-9. Epub 2014 Mar 14 PubMed: 24679837PAPER Nordberg A, Forsberg A, Engler H
Amyloid imaging in MCI patients
Neurobiol Aging 2006; 27(Suppl 1):S6.Tatiana Marcal
San Francisco Clinical Research CenterSan Francisco
PBT2 Takes a Dive in Phase 2 Alzheimer’s Trial
RESEARCH NEWS 2014-04-01 Research News On March 31, the Australian company Prana Biotechnology announced negative top-line results of its only Phase 2 study of the anti-amyloid drug PBT2. Called IMAGINE, the trial had enrolled 42 people with prodromal or mild Alzheimer’s disease
Jinte Middeldorp
Stanford University
PAPER Hegde ML, Anitha S, Jagannatha KS
Are Monomer-Oligomer Aggregates of Amyloidogenic Peptides Toxic Species in Neurodegeneration
Neurobiol Aging 2004; 25(Suppl 2):S170.PAPER Bliwise DL, Hughes M, McMahon PM, Kutner N
Observed sleep/wakefulness and severity of dementia in an Alzheimer's disease special care unit.
J Gerontol A Biol Sci Med Sci. 1995 Nov;50(6):M303-6. PubMed: 7583801Current Filters
No filters selected